A LONG-TERM FOCUS
                  ON INNOVATION

                  We welcome the opportunity to discuss:

                  BUSINESS
                  DEVELOPMENT
                  COLLABORATIONS

                  • In-licensing and / or R&D collaborations
                    • Creative collaborations in emerging fields
                    • Best-in-class technology platforms and capabilities to enhance the Regeneron antibody pipeline
                  • Strategic late-stage development and commercial partnerships with other leading biopharma companies
                  • Collaborations that maximize the global potential of our pipeline and ability to deliver new medicines to patients around the globe

                  Introduce your assets or discuss
                  late-stage partnership

                  ACADEMIC &
                  RESEARCH
                  COLLABORATIONS

                  • Non-Clinical Research Collaborations providing investigators from academic and research institutions access to our:

                  Learn more

                  • Clinical Collaborations / Investigator Initiated Studies (IIS) providing investigators and clinicians access to and / or funding for our:

                  Learn more

                  OUR BUSINESS DEVELOPMENT STRATEGY

                  Our entrepreneurial culture and history as one of the industry’s longest-standing biotech companies fosters a high-science mindset, nimble decision-making and highly collaborative relationships.

                  We follow the science, rather than limiting our innovations to any one therapeutic area. We are open to collaboration opportunities with the potential to offer important benefits to patients, representing a true scientific or medical advance. In particular, we consider:

                  • Novel platforms that enable next-generation therapeutics
                  • Technologies for antibody discovery and development against new / challenging targets
                  • New approaches that enhance activity of tumor-directed antibodies
                  • Biomarker discovery and validation
                  • Drug delivery or formulation technologies that improve the efficacy / safety profile, address a CMC or supply challenge or enhance patient convenience or compliance
                  • Studying the potential of combinations pairing our pipeline molecules with other innovative clinical-stage therapeutic candidates
                  • Collaborations with leading academic groups to advance our efforts in human genetics, animal model development, target discovery, target validation and antibody discovery

                  SOME OF OUR CURRENT COLLABORATORS INCLUDE:


                  BAYER logo

                  Global ophthalmology
                  collaborations

                  SANOFI logo

                  Antibody and immunotherapy
                  collaborations

                  Icahn School of Medicine at Mount Sinai logo

                  Antibody discovery
                  agreement

                  Columbia University logo

                  Research collaboration on genetic
                  basis of familial disease

                  TEVA logo

                  Global collaboration for
                  investigational pain therapeutic

                  Intellia Therapeutics logo

                  Gene-editing technology
                  collaboration

                  Adicet Bio logo

                  Engineered immune cell
                  therapeutics collaboration

                  Alnylam Pharmaceuticals logo

                  RNA interference (RNAi)
                  therapeutics collaboration

                  91福利国产在线观看